Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
11 April 2018
E-000314/2018
Answer given by Mr Andriukaitis on behalf of the Commission

1. The Commission does not plan to appoint an EU coordinator for dementia.

The Commission is working closely with a number of Member States on dementia through the second Joint Action ‘Act on Dementia’ funded under the EU Health Programme(1) and launched in March 2016.

2. One of the focus areas of the Joint Action with a dedicated work package is diagnosis and post-diagnostic support. It aims to provide Members States with clear, evidence-based and tested information and recommendations on how to implement change and improvement in dementia diagnosis rates and post-diagnostic supports and in using different tools and approaches for diagnosis for people with dementia.

Consensus towards a diagnosis approach for cognitive disorders has already been reached between the partners and will be published in due course.

A report on testing evidence-based examples of best practice in dementia diagnosis will be produced at the end of the Joint Action in 2019.

3. The Commission has been supporting with growing intensity, brain research for many years through the framework Programmes, reaching some EUR 500 million a year for both basic and translational research. Specifically for Alzheimer, EUR 544 million supported 370 projects over the past 10 years.

This investment includes support for the development of novel diagnostic tools' and new therapies. In addition, the Innovative Medicines Initiative (IMI2)(2), is promoting research on early detection and new drug targets for Alzheimer, with projects such as EPAD(3), BRIDGET(4) and DACAPO-AD(5) funded by the EU Joint Programming Initiative on Neurodegenerative Diseases which ensures a better coordination of Member States' efforts on Alzheimer.

(1)https://webgate.ec.europa.eu/chafea_pdb/health/projects/678481
(2)https://www.imi.europa.eu/
(3)http://www.imi.europa.eu/content/epad
(4)http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/Fact-Sheet_BRIDGET_v2.pdf
(5)http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/Factsheet_DACAPO-AD.pdf

Last updated: 11 April 2018Legal notice